FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169153889> ?p ?o ?g. }

• W3169153889 abstract "Erythrodermic psoriasis (EP) is a life-threatening condition characterized by a severe erythema affecting at least 80%–90% of the body surface area.1 Systemic symptoms such as fever, tachycardia, lymphadenopathy, arthralgia and fatigue can be associated with EP.1 Here we describe a case of a 61-year-old man referring to our Department in September 2020. The patient reported a sudden worsening of his long-duration psoriasis (35 years): on clinical examination skin lesions were extended to 90% of body surface area (BSA), for a total Psoriasis Area Severity Index (PASI) of 38 (Figure 1). He also complaint of fatigue and chills. In addition, the patient suffered from hypertension treated with ace inhibitors and obesity. Previous psoriasis treatments included only topicals and heliotherapy. Because of the severity of the disease, the disabling impact on the patient's quality of life and the patient's refusal to conventional therapy for safety concerns, he was screened for biological therapy. In order to increase patient's compliance to treatment and to give an effective and safe therapy, Tildrakizumab was chosen, due to the lowest number of administrations required among biologics (1 s.c. injection every 12 weeks after the induction phase), as requested from the patient. Tildrakizumab at labeled dosage was started (100 mg at weeks 0, 4, and every 12 weeks thereafter). At 4-week follow-up, PASI decreased to 7.8 and BSA to 25%; PASI75 response was rapidly reached (Figure 1). At week 16, a complete resolution of skin lesions (PASI100) was achieved (Figure 1), along with a substantial improvement of the fatigue symptom. Before the introduction of biologic therapy, first-line options for the treatment of EP were based on traditional systemic therapy: methotrexate, acitretin, and cyclosporine.2 Later on, the introduction of biologics has provided for faster and safer results for EP: indeed, several case reports support the use of biologic therapy as first-line treatment for EP.3 Although the severity and the rarity of this condition do not allow the inclusion of EP patients in clinical studies, the current literature is supplying evidences from real world experiences (RWEs). Currently, as pointed out by a systematic review, positive responses have been described in cases treated by different classes of biologics, from anti-TNF-α to anti-IL23.3, 4 Up until now, no case describing EP successfully treated by the latest anti-IL23 approved in Europe,5 Tildrakizumab, has been described. Here we firstly report a case of a 61-year old man with EP successfully and safely treated by Tildrakizumab. A significant improvement was experienced since the first follow up at week 4, thus giving the patient the possibility to benefit from a better quality of life in a short time of treatment. Although our study reports only a single case of EP treated by Tildrakizumab, further experiences could widen the therapeutical horizons of biologics, even the latest ones, to evaluate their efficacy and safety for EP. In conclusion, our case is part of the literature reports from RWEs that could have a significant role to establish the best therapeutic algorithm and tailored options for EP patients. The authors declare no potential conflict of interest. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study." @default.
• W3169153889 created "2021-06-22" @default.
• W3169153889 creator A5015814702 @default.
• W3169153889 creator A5026402548 @default.
• W3169153889 creator A5054838950 @default.
• W3169153889 creator A5080991532 @default.
• W3169153889 date "2021-06-22" @default.
• W3169153889 modified "2023-10-11" @default.
• W3169153889 title "Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?" @default.
• W3169153889 cites W2061352082 @default.
• W3169153889 cites W2910616351 @default.
• W3169153889 cites W2984218665 @default.
• W3169153889 cites W3088684759 @default.
• W3169153889 doi "https://doi.org/10.1111/dth.15030" @default.
• W3169153889 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8596402" @default.
• W3169153889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34137492" @default.
• W3169153889 hasPublicationYear "2021" @default.
• W3169153889 type Work @default.
• W3169153889 sameAs 3169153889 @default.
• W3169153889 citedByCount "23" @default.
• W3169153889 countsByYear W31691538892021 @default.
• W3169153889 countsByYear W31691538892022 @default.
• W3169153889 countsByYear W31691538892023 @default.
• W3169153889 crossrefType "journal-article" @default.
• W3169153889 hasAuthorship W3169153889A5015814702 @default.
• W3169153889 hasAuthorship W3169153889A5026402548 @default.
• W3169153889 hasAuthorship W3169153889A5054838950 @default.
• W3169153889 hasAuthorship W3169153889A5080991532 @default.
• W3169153889 hasBestOaLocation W31691538891 @default.
• W3169153889 hasConcept C126322002 @default.
• W3169153889 hasConcept C141071460 @default.
• W3169153889 hasConcept C16005928 @default.
• W3169153889 hasConcept C2776173921 @default.
• W3169153889 hasConcept C2777011040 @default.
• W3169153889 hasConcept C2777501473 @default.
• W3169153889 hasConcept C2778570526 @default.
• W3169153889 hasConcept C2778594517 @default.
• W3169153889 hasConcept C2779121184 @default.
• W3169153889 hasConcept C2780564577 @default.
• W3169153889 hasConcept C71924100 @default.
• W3169153889 hasConceptScore W3169153889C126322002 @default.
• W3169153889 hasConceptScore W3169153889C141071460 @default.
• W3169153889 hasConceptScore W3169153889C16005928 @default.
• W3169153889 hasConceptScore W3169153889C2776173921 @default.
• W3169153889 hasConceptScore W3169153889C2777011040 @default.
• W3169153889 hasConceptScore W3169153889C2777501473 @default.
• W3169153889 hasConceptScore W3169153889C2778570526 @default.
• W3169153889 hasConceptScore W3169153889C2778594517 @default.
• W3169153889 hasConceptScore W3169153889C2779121184 @default.
• W3169153889 hasConceptScore W3169153889C2780564577 @default.
• W3169153889 hasConceptScore W3169153889C71924100 @default.
• W3169153889 hasIssue "5" @default.
• W3169153889 hasLocation W31691538891 @default.
• W3169153889 hasLocation W31691538892 @default.
• W3169153889 hasLocation W31691538893 @default.
• W3169153889 hasOpenAccess W3169153889 @default.
• W3169153889 hasPrimaryLocation W31691538891 @default.
• W3169153889 hasRelatedWork W1485326008 @default.
• W3169153889 hasRelatedWork W1989170203 @default.
• W3169153889 hasRelatedWork W2039876145 @default.
• W3169153889 hasRelatedWork W2415983218 @default.
• W3169153889 hasRelatedWork W2526632411 @default.
• W3169153889 hasRelatedWork W2545526290 @default.
• W3169153889 hasRelatedWork W2746394032 @default.
• W3169153889 hasRelatedWork W2766413417 @default.
• W3169153889 hasRelatedWork W2893132787 @default.
• W3169153889 hasRelatedWork W2949233710 @default.
• W3169153889 hasVolume "34" @default.
• W3169153889 isParatext "false" @default.
• W3169153889 isRetracted "false" @default.
• W3169153889 magId "3169153889" @default.
• W3169153889 workType "article" @default.